Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-04-25 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于2022年年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (308 characters) stating that the company's 2022 Annual Report and its summary have been disclosed on a regulatory website. It does not contain the actual report or financial data but merely informs investors where to find the report. According to the 'Menu vs Meal' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2023-04-25 Chinese
独立董事关于第四届董事会第二十二次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various proposals related to the company's 2022 annual matters, including profit distribution, remuneration, internal control self-evaluation report, fundraising usage report, related party transactions, financing authorization, appointment of a deputy general manager, and changes to company name and articles of association. It references the 2022 annual shareholders' meeting and various regulatory rules. The document is a formal opinion letter from independent directors on agenda items to be submitted to the 2022 annual general meeting, not the actual annual report or financial statements. The length is about 2400 characters, which is relatively short and consistent with an opinion or announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement/opinion related to the annual meeting agenda items but does not contain the full annual report or financial statements itself.
2023-04-25 Chinese
新乡拓新药业股份有限公司2022年度募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds" for the year 2022. It is issued by an accounting firm (信永中和会计师事务所) and contains detailed information about the company's fundraising amount, usage, storage, and management of the raised funds during the fiscal year 2022. The document includes financial figures, project investment details, changes in project implementation, and compliance with regulatory requirements. It is a specialized report focusing on the verification of the use and storage of raised funds, not a full annual report or earnings release. It is not a mere announcement or certification but a detailed verification report. This fits the category of an Audit Report / Information (AR), which includes standalone audit or verification reports related to specific financial aspects, excluding full annual reports. The document length (12,780 characters) and content depth confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2022
2023-04-25 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023年第一季度报告" which translates to "2023 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. Given the detailed quarterly financial data and the reporting period being a quarter, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-25 Chinese
独立董事2022年度述职报告（靳焱顺）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2022 Annual Work Report" for the company 新乡拓新药业股份有限公司. It details the independent director's attendance at board and shareholder meetings, opinions on various board matters, participation in committees, and other duties performed during the year 2022. The content is a detailed report of the independent director's activities and responsibilities over the year, which aligns with a management or board-related report rather than a financial report or announcement. It is not an Annual Report (10-K), Audit Report, or Earnings Release. It is not a short announcement or certification but a substantive report on board/management activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3220 characters, which is substantive for this type of report. Confidence is high due to clear content and purpose.
2023-04-25 Chinese
关于拟变更公司名称、住所、经营范围及修订《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Xinxiang Tuoxin Pharmaceutical Co., Ltd. regarding proposed changes to the company name, address, business scope, and amendments to the company bylaws (Articles of Association). It includes details of board resolutions, independent director opinions, and states that these changes will be submitted to the 2022 Annual General Meeting for approval. The document is a formal announcement of corporate governance changes and does not contain financial statements or detailed financial data. It is not a full annual report, interim report, or earnings release. It is also not a proxy solicitation or voting results announcement. The content focuses on board/management decisions and company structural changes. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters and is a direct announcement, not a report publication notice or certification letter, so RPA or RNS are less suitable.
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.